Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05959473Not ApplicableWithdrawn

EGFR_IUO 3.20 Clinical Study Protocol

Role: lead

NCT05833412Unknown

Molecular Early Sepsis Identification Study

Role: collaborator

NCT04236102Not ApplicableCompleted

KEBI-Cyto Study - Use of the Biocartis Idylla

Role: collaborator

NCT04086680Completed

The Detection of EGFR Mutations in Liquid Based Cytology Samples

Role: collaborator

NCT01905033Unknown

Molecular Diagnosis and Risk Stratification of Sepsis

Role: collaborator

All 5 trials loaded